Nuvation Bio

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2023, and provided a business update. “We remain focused on strong clinical execution of our NUV-868 program for advanced solid tumors,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvat.

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio is developing BET inhibitors for solid tumors, with lead asset NUV-868 in phase 1/1b trials. BET proteins play a role in gene regulation and chromatin remodeling, and inhibiting them may be therapeutic for cancer. NUV-868 is highly selective for BD2, potentially reducing toxicity compared to other BET inhibitors.

Nuvation: Cash Is King, Science Is An Afterthought

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2023, and provided a business update. "We continue to enroll patients in the Phase 1 and Phase 1b studies of NUV-868 where dose escalation is ongoing. We also look forward to expanding our pipeline as we progress our fir.

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the formation of a Scientific Advisory Board. The Scientific Advisory Board will work alongside the Nuvation Bio management team to advance its pipeline of therapeutic candidates for some of the most difficult-to-treat cancers. “We are proud to announce the formation of Nuvation.

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2023, and provided a business update. “We saw strong clinical execution in the first quarter as we continued to enroll patients in the Phase 1 monotherapy and Phase 1b combination studies of NUV-868,” said David Hung, M.

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Archer Aviation

Faraday Future Intelligent Electric

First Republic

Mullen Automotive

Prelude Therapeutics

GeneDx Holdings Corp

Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a flood of messages from people defending the honor of corporations who could care less about them.

The 7 Worst Stocks to Buy Now

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a business update. “In the fourth quarter, we dosed the first patient in both dosing regimens of our Phase 1b study of NUV-868 in combination with olaparib or enzalutamide.

Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

NEW YORK--( BUSINESS WIRE )--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced it has dosed the first patient in a Phase 1b study of its BD2-selective BET inhibitor, NUV-868, in combination with olaparib.

Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the third quarter ended September 30, 2022, and provided a business update.

Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2022, and provided a business update. “We are committed to advancing innovative therapies as quickly and safely as possible for people with cancers that do not currently have adequate treatment options. As previously ann

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422. The decision to discontinue clinical development of NUV-422 is the result of an internal risk-benefit analysis factoring in feedback received

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Inc. (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock?

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer. Dr. Liu will lead Nuvation Bio's clinical development team and collaborate with the executive committee to provide strategic direction for the Company's research

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

NEW YORK , July 13, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or the "Company") (NYSE: NUVB). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

Los Angeles, California--(Newsfile Corp. - July 1, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or "the Company") (NYSE: NUVB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nuvation issued a press release on June 27, 2022, "announc[ing] the...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 30, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Nuvation Bio Inc. ("Nuvation" or "the Company") (NYSE: NUVB) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Nuvation issued a press release on June 27, 2022, "announc[ing] the...

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NUVB #NUVB--The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

The FDA has placed a partial clinical hold on Nuvation Bio Inc's (NYSE: NUVB) Phase 1 dose-escalation study of NUV-422 in solid tumors. The company's Phase 1 trial began enrolling patients in December 2020 and, in recent months, was exploring higher doses to define a.

FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The Company's P

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the first quarter ended March 31, 2022, and provided a business update. “We are encouraged by the important progress we have made so far this year across our pipeline of novel oncology therapeutic candidates for difficult-to-treat cancers. In the first q

Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update

NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update. “In 2021, the Nuvation Bio team made significant progress for our lead cyclin-dependent kinase 2/4/6 inhibitor program in the clinic. NUV-422 received FDA Fast Track De

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Nuvation (NUVB) will be initiating a phase I/II study of NUV-868 as a monotherapy and in combination with Lynparza or Xtandi in multiple tumor types following IND clearance by the FDA.

Nuvation (NUVB) Gets FDA Clearance for Oncology Candidate

The FDA has signed off Nuvation Bio Inc's (NYSE: NUVB) investigational new drug (IND) application to evaluate NUV-868 to treat advanced solid tumors. NUV-868 inhibits BRD4, a key member of the BET family that epigenetically regulates proteins that control tumor growth and differentiation.

FDA clears Nuvation Bio's IND Application For NUV-868 In Advanced Solid Tumors

NEW YORK, Jan. 20, 2022 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-868, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor, for the treatment of advanced solid tumors, including ovarian cancer, pancreatic cancer, metastatic castration resistant prostate cancer (mCRPC), and triple negative breast cancer (TNBC). "The clearance of our IND application for NUV-868 is an important milestone for Nuvation Bio as it marks the fourth IND in the last 14 months across our deep pipeline of innovative cancer therapeutics targeting multiple tumor types," said David Hung, M.D.

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors

David Hung, M.D., founder, president, and chief executive officer, to present virtually at the 40th Annual J.P.

News for Nuvation Bio Stock (NUVB)